International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-3 doi: 10.5281/zenodo.8076650
Original Article
Assessment of Quality of Life in Children with Type 1 Diabetes Mellitus
 ,
Published
June 24, 2023
Abstract
Background: Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease that affects children and adults. It requires continuous insulin administration for glucose control. T1DM significantly impacts children's quality of life (QOL), affecting their daily activities and causing emotional and social challenges. Aim: The current study aims to assess the effect of Type 1 DM on the quality of life of children who seek treatment for the disease. Methodology: This cross-sectional study included 60 children with Type 1 Diabetes Mellitus (T1DM) divided into two age groups. The Pediatric Quality of Life Inventory (PedsQL) questionnaire assessed their quality of life from Physical, Emotional, Social and Schooling dimensions. Results: The study on children with Type 1 Diabetes Mellitus (T1DM) aimed to examine the differences in quality of life based on age and gender. The participants were divided into two age groups: 8-12 years and 13-18 years, with most children falling into the 8-12 years category. Male children constituted a higher proportion compared to females. Significant differences were found between the age groups across various dimensions of quality of life, with the 8-12 years group generally reporting higher scores. However, no significant gender differences were observed. Children with T1DM face physical, emotional, social, and schooling challenges, indicating the condition's impact on their lives. Conclusion: This study emphasizes the multidimensional impact of T1DM on children's quality of life and suggests targeted interventions. By addressing these multidimensional factors, we can better meet the needs of children with T1DM and improve their overall well- being.
Recommended Articles
Loading Image...
Volume-4, Issue-3
Citations
2887 Views
468 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved